Zhen Zhou1, Richard Ofori-Asenso2, Andrea J Curtis3, Monique Breslin4, Rory Wolfe3, John J McNeil3, Anne M Murray5, Michael E Ernst6, Christopher M Reid7, Jessica E Lockery3, Robyn L Woods3, Andrew M Tonkin3, Mark R Nelson4. 1. Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia. Electronic address: zhen.zhou@utas.edu.au. 2. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Copenhagen Centre for Regulatory Science, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 3. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. 4. Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia. 5. Berman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute, Division of Geriatrics, Department of Medicine, Hennepin HealthCare, Minneapolis, Minnesota; University of Minnesota, Minneapolis, Minnesota. 6. Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, Iowa; Department of Family Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa. 7. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; School of Public Health, Curtin University, Perth, Western Australia, Australia.
Abstract
BACKGROUND: There is clinical uncertainty regarding the benefits and harms of prescribing statins in healthy subjects ≥70 years of age. OBJECTIVES: The aim of this study was to examine the association among statins, dementia-free and disability-free survival, and cardiovascular disease (CVD) among healthy older adults using data from the ASPREE (Aspirin in Reducing Events in the Elderly) trial. METHODS: ASPREE was a randomized trial of 19,114 community-dwelling persons in Australia and the United States ≥65 years of age and free of documented CVD, dementia, and disability. Data were collected for those ≥70 years of age, and participants who took statins at baseline were compared with those who did not using Cox proportional hazards regression with inverse probability weighting. The primary outcome, referred to as "disability-free survival," was a composite of all-cause mortality, dementia, or persistent physical disability. Other outcomes included the individual components of the composite outcome, major adverse cardiovascular events, fatal CVD, myocardial infarction, and stroke. RESULTS: Of the 18,096 included participants (median age 74.2 years, 56.0% women), 5,629 took statins at baseline. Over a median follow-up period of 4.7 years, baseline statin use was not associated with disability-free survival or with the risk for all-cause mortality or dementia. However, it was associated with lower risks for physical disability and all cardiovascular outcomes. CONCLUSIONS: Among healthy community-dwelling adults ≥70 years of age, statin use may be beneficial for preventing physical disability and CVD but not beneficial for prolonging disability-free survival or avoiding death or dementia. Future clinical trials are needed to confirm these findings.
RCT Entities:
BACKGROUND: There is clinical uncertainty regarding the benefits and harms of prescribing statins in healthy subjects ≥70 years of age. OBJECTIVES: The aim of this study was to examine the association among statins, dementia-free and disability-free survival, and cardiovascular disease (CVD) among healthy older adults using data from the ASPREE (Aspirin in Reducing Events in the Elderly) trial. METHODS:ASPREE was a randomized trial of 19,114 community-dwelling persons in Australia and the United States ≥65 years of age and free of documented CVD, dementia, and disability. Data were collected for those ≥70 years of age, and participants who took statins at baseline were compared with those who did not using Cox proportional hazards regression with inverse probability weighting. The primary outcome, referred to as "disability-free survival," was a composite of all-cause mortality, dementia, or persistent physical disability. Other outcomes included the individual components of the composite outcome, major adverse cardiovascular events, fatal CVD, myocardial infarction, and stroke. RESULTS: Of the 18,096 included participants (median age 74.2 years, 56.0% women), 5,629 took statins at baseline. Over a median follow-up period of 4.7 years, baseline statin use was not associated with disability-free survival or with the risk for all-cause mortality or dementia. However, it was associated with lower risks for physical disability and all cardiovascular outcomes. CONCLUSIONS: Among healthy community-dwelling adults ≥70 years of age, statin use may be beneficial for preventing physical disability and CVD but not beneficial for prolonging disability-free survival or avoiding death or dementia. Future clinical trials are needed to confirm these findings.
Authors: Michelle C Odden; Mark J Pletcher; Pamela G Coxson; Divya Thekkethala; David Guzman; David Heller; Lee Goldman; Kirsten Bibbins-Domingo Journal: Ann Intern Med Date: 2015-04-21 Impact factor: 25.391
Authors: Sonal Singh; Susan Zieman; Alan S Go; Stephen P Fortmann; Nanette K Wenger; Jerome L Fleg; Barbara Radziszewska; Neil J Stone; Sophia Zoungas; Jerry H Gurwitz Journal: J Am Geriatr Soc Date: 2018-10-02 Impact factor: 5.562
Authors: Katherine Samaras; Steve R Makkar; John D Crawford; Nicole A Kochan; Melissa J Slavin; Wei Wen; Julian N Trollor; Henry Brodaty; Perminder S Sachdev Journal: J Am Coll Cardiol Date: 2019-11-26 Impact factor: 24.094
Authors: Michael G Nanna; Ann Marie Navar; Tracy Y Wang; Xiaojuan Mi; Salim S Virani; Michael J Louie; L Veronica Lee; Anne C Goldberg; Veronique L Roger; Jennifer Robinson; Eric D Peterson Journal: J Am Heart Assoc Date: 2018-05-08 Impact factor: 5.501
Authors: Douglas E Long; Kate Kosmac; Cory M Dungan; Marcas M Bamman; Charlotte A Peterson; Philip A Kern Journal: Front Physiol Date: 2022-04-14 Impact factor: 4.755
Authors: Zhen Zhou; Andrea J Curtis; Michael E Ernst; Joanne Ryan; Sophia Zoungas; Rory Wolfe; John J McNeil; Anne M Murray; Christopher M Reid; Enayet K Chowdhury; Robyn L Woods; Andrew M Tonkin; Mark R Nelson Journal: Eur J Clin Pharmacol Date: 2021-10-26 Impact factor: 2.953
Authors: Kamal Awad; Maged Mohammed; Mahmoud Mohamed Zaki; Abdelrahman I Abushouk; Gregory Y H Lip; Michael J Blaha; Carl J Lavie; Peter P Toth; J Wouter Jukema; Naveed Sattar; Maciej Banach Journal: BMC Med Date: 2021-06-22 Impact factor: 8.775
Authors: Carlos Lahoz; Juan Cárdenas-Valladolid; Miguel Ángel Salinero-Fort; José María Mostaza Journal: Aging Clin Exp Res Date: 2021-08-07 Impact factor: 4.481